Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone415-483-8800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$51.49 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable
Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions
What is Ultragenyx Pharmaceutical's stock symbol?
Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."
How were Ultragenyx Pharmaceutical's earnings last quarter?
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) issued its quarterly earnings results on Monday, May, 6th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.73) by $0.09. The biopharmaceutical company earned $18.17 million during the quarter, compared to analysts' expectations of $18.75 million. Ultragenyx Pharmaceutical had a negative return on equity of 51.00% and a negative net margin of 550.30%. The company's revenue for the quarter was up 70.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.63 EPS. View Ultragenyx Pharmaceutical's Earnings History.
When is Ultragenyx Pharmaceutical's next earnings date?
What price target have analysts set for RARE?
15 equities research analysts have issued twelve-month price objectives for Ultragenyx Pharmaceutical's stock. Their predictions range from $59.00 to $95.00. On average, they expect Ultragenyx Pharmaceutical's stock price to reach $78.9333 in the next twelve months. This suggests a possible upside of 28.5% from the stock's current price. View Analyst Price Targets for Ultragenyx Pharmaceutical.
What is the consensus analysts' recommendation for Ultragenyx Pharmaceutical?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ultragenyx Pharmaceutical.
Has Ultragenyx Pharmaceutical been receiving favorable news coverage?
Media headlines about RARE stock have been trending somewhat positive recently, according to InfoTrie. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ultragenyx Pharmaceutical earned a media sentiment score of 1.9 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are some of Ultragenyx Pharmaceutical's key competitors?
Some companies that are related to Ultragenyx Pharmaceutical include GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GNMSF), Mylan (MYL), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Marina Biotech (MRNA), Alnylam Pharmaceuticals (ALNY), Loxo Oncology (LOXO) and Perrigo (PRGO).
What other stocks do shareholders of Ultragenyx Pharmaceutical own?
Who are Ultragenyx Pharmaceutical's key executives?
Ultragenyx Pharmaceutical's management team includes the folowing people:
- Emil D. Kakkis, President, Chief Executive Officer & Director
- Wladimir Hogenhuis, Chief Operating Officer
- Shalini Sharp, Chief Financial Officer & Executive Vice President
- Dennis Karl Huang, Chief Technical Operations Officer & Senior VP
- Eric Crombez, Chief Medical Officer
Who are Ultragenyx Pharmaceutical's major shareholders?
Ultragenyx Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (11.10%), BlackRock Inc. (8.28%), FMR LLC (4.38%), First Trust Advisors LP (3.24%), Federated Investors Inc. PA (3.05%) and Geode Capital Management LLC (1.17%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.
Which institutional investors are selling Ultragenyx Pharmaceutical stock?
RARE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Pictet Asset Management Ltd., Morgan Stanley, Schonfeld Strategic Advisors LLC, Xact Kapitalforvaltning AB, WS Management Lllp, Los Angeles Capital Management & Equity Research Inc. and Bank of Montreal Can. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Insider Buying and Selling for Ultragenyx Pharmaceutical.
Which institutional investors are buying Ultragenyx Pharmaceutical stock?
RARE stock was bought by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, First Trust Advisors LP, Wellington Management Group LLP, Macquarie Group Ltd., BlackRock Inc., Goldman Sachs Group Inc., SG Americas Securities LLC and Voya Investment Management LLC. View Insider Buying and Selling for Ultragenyx Pharmaceutical.
How do I buy shares of Ultragenyx Pharmaceutical?
Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ultragenyx Pharmaceutical's stock price today?
One share of RARE stock can currently be purchased for approximately $61.43.
How big of a company is Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical has a market capitalization of $3.53 billion and generates $51.49 million in revenue each year. The biopharmaceutical company earns $-197,610,000.00 in net income (profit) each year or ($7.39) on an earnings per share basis.
What is Ultragenyx Pharmaceutical's official website?
How can I contact Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]
MarketBeat Community Rating for Ultragenyx Pharmaceutical (NASDAQ RARE)
MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe RARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
